# Andrew Barnell

> Andrew Barnell is the co-founder and CEO of Geneoscopy, a St. Louis life sciences company that turned a sibling conversation about a missed colonoscopy into ColoSense, the first FDA-approved stool RNA test for colorectal cancer screening. A Cornell economics graduate and Wharton MBA who started in J.P. Morgan's healthcare investment banking group and private equity at Lindsay Goldberg, Barnell paired his finance background with the scientific work of his sister and co-founder Erica Barnell, MD/PhD, to build a company that has raised more than $217 million and earned FDA approval for a noninvasive screening test built on patented RNA biomarker technology.

- **Role:** Co-Founder and Chief Executive Officer at Geneoscopy
- **Organizations:** Geneoscopy, J.P. Morgan (former), Lindsay Goldberg (former)
- **Nationality:** American
- **Education:** B.S. in Applied Economics & Management, specialization in Finance, Cornell University, MBA in Health Care Management and Entrepreneurial Management, The Wharton School, University of Pennsylvania
- **Known for:** Co-founded Geneoscopy and serves as CEO, Led the company to FDA approval of ColoSense, the first multitarget stool RNA (mt-sRNA) test for colorectal cancer screening, Raised more than $217 million in total funding, including a $105M Series C led by Bio-Rad Laboratories

## Career timeline

- **—** — Began career as a financial analyst in J.P. Morgan's healthcare investment banking group, working on M&A and capital markets transactions
- **—** — Worked as an associate at Lindsay Goldberg, a middle-market private equity firm focused on family-owned businesses
- **2015** — Co-founded Geneoscopy with his sister, Erica Barnell, MD/PhD
- **2024** — Geneoscopy received FDA approval for ColoSense, a noninvasive stool RNA colorectal cancer screening test
- **2025** — Closed a $105M Series C round led by Bio-Rad Laboratories; named EY Entrepreneur Of The Year Heartland finalist with co-founder Erica Barnell

## Achievements

- Co-founded Geneoscopy and serves as CEO
- Led the company to FDA approval of ColoSense, the first multitarget stool RNA (mt-sRNA) test for colorectal cancer screening
- Raised more than $217 million in total funding, including a $105M Series C led by Bio-Rad Laboratories
- Named a finalist for the EY Entrepreneur Of The Year 2025 Heartland Award alongside co-founder Erica Barnell

## Latest updates

- **2025-01** — Geneoscopy closed a $105M Series C funding round led by Bio-Rad Laboratories to commercialize ColoSense and expand its diagnostic pipeline.
- **2025-04** — Andrew and Erica Barnell named finalists for the EY Entrepreneur Of The Year 2025 Heartland Award.

## Links

- Website: https://geneoscopy.com
- LinkedIn: http://www.linkedin.com/in/andrewbarnell

---

Profile page: https://yespress.io/andrew-barnell
Published by YesPress — https://yespress.io
Last updated: 2026-06-14